Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group Study to Evaluate the Effect of Umeclidinium (UMEC) Added to Inhaled Corticosteroid/ Long-acting Beta-agonist Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease COPD

NCT02257372 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02257372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group Study to Evaluate the Effect of Umeclidinium (UMEC) Added to Inhaled Corticosteroid/ Long-acting Beta-agonist Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease COPD
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2014
Completion date
March 24, 2015
Enrollment
236 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive